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Background:  Galectin-3 (Gal-3), a β-galactoside-binding lectin, has been implicated in cardiac remodeling and fibrosis. The prognostic 
utility of Gal-3 in patients (pts) after ACS is not well established.
methods:  Gal-3 was measured at baseline in 4964 pts from SOLID-TIMI 52 ≤30 days post ACS (median f/u 2.5 y). Analyses were adjusted 
for demographics, med hx, eGFR, time from event, index diagnosis, catheterization and treatment arm. Additional analyses included 
troponin (hsTnI) and BNP. Analytes were measured with Abbott ARCHITECT.
results:  Higher Gal-3 concentration was associated with a higher unadjusted risk of CV death and HF hospitalization (P<0.001, Fig A). 
After adjustment for clinical predictors, Gal-3 above the median was associated with a 54% higher risk of CV death or HF vs. those below 
(HR 1.54, 95% CI 1.2-1.97). Increasing Gal-3 levels were associated with an increased risk of CV death or HF (HR per SD 1.26, 95% CI 
1.13-1.40), as well as its individual components (CV Death: HR 1.24, 95% CI 1.08-1.43; HF: HR 1.30, 95% CI 1.12-1.50). This relationship 
remained significant after hsTnI and BNP were included in the model (CVD/HF: HR per SD 1.22, 95% 1.09-1.37). In a multimarker 
approach, Gal-3 provided incremental information to BNP for risk stratification (Fig B).
conclusion:  Gal-3 concentration is associated with the risk of CV death and HF hospitalization in pts after ACS independent of hsTnI and 
BNP. These findings point to Gal-3 as a potential tool for guiding therapy aimed at HF prevention post-ACS.
